# Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma

> **NCT01037478** · PHASE2 · COMPLETED · sponsor: **4SC AG** · enrollment: 37 (actual)

## Conditions studied

- Hodgkin's Lymphoma

## Interventions

- **DRUG:** Resminostat (4SC-201)

## Key facts

- **NCT ID:** NCT01037478
- **Lead sponsor:** 4SC AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2012-01
- **Final completion:** 2013-03
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2014-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01037478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01037478, "Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01037478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*